From conventional to stealth liposomes: a new frontier in cancer chemotherapy

被引:86
作者
Cattel, L [1 ]
Ceruti, M [1 ]
Dosio, F [1 ]
机构
[1] Univ Turin, Dipartimento Sci & Tecnol Farmaco, I-10125 Turin, Italy
关键词
liposomes; antitumor liposomes; pegylated liposomal doxorubicin;
D O I
10.1179/joc.2004.16.Supplement-1.94
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this review, the different types of liposome used in medicine, in particular in the field of antitumor therapy, are focalised, emphasizing their structures, pharmacological action, pharmacokinetics and biodistribution, toxicity profiles and in the main clinical applications. The first-generation liposomes (conventional liposomes) comprised a liposome-containing amphotericin B, Ambisome, and Myocet, doxorubicin-containing liposome used in clinical trials to treat metastatic breast cancer. The last generation liposomes were pegylated liposomal doxorubicin (Caelix), called "stealth liposomes" because of their ability to evade interception by the immune system, characterized by very long-circulation half-life, favourable pharmacokinetic behaviour and specific accumulation in tumor tissues.
引用
收藏
页码:94 / 97
页数:4
相关论文
共 12 条
  • [1] BANGHAM AD, 1980, LIPOSOMES BIOL SYSTE, pCH1
  • [2] Forssen Eric A., 1994, Journal of Liposome Research, V4, P481, DOI 10.3109/08982109409037058
  • [3] GABIZON A, 1994, CANCER RES, V54, P987
  • [4] Long-circulating liposomes for drug delivery in cancer therapy: A review of biodistribution studies in tumor-bearing animals
    Gabizon, A
    Goren, D
    Horowitz, AT
    Tzemach, D
    Lossos, A
    Siegal, T
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1997, 24 (2-3) : 337 - 344
  • [5] GORDON KB, 1995, CANCER, V75, P2169, DOI 10.1002/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO
  • [6] 2-H
  • [7] LIPOSOMAL AMPHOTERICIN-B (AMBISOME) - SAFETY DATA FROM A PHASE-II/III CLINICAL-TRIAL
    MEUNIER, F
    PRENTICE, HG
    RINGDEN, O
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 : 83 - 91
  • [8] Safra T, 2001, CANCER, V91, P90, DOI 10.1002/1097-0142(20010101)91:1<90::AID-CNCR12>3.3.CO
  • [9] 2-1
  • [10] Pegylated liposomal doxorubicin (doxil):: Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2
    Safra, T
    Muggia, F
    Jeffers, S
    Tsao-Wei, DD
    Groshen, S
    Lyass, O
    Henderson, R
    Berry, G
    Gabizon, A
    [J]. ANNALS OF ONCOLOGY, 2000, 11 (08) : 1029 - 1033